MIT researchers have genetically engineered E.coli bacteria to replicate light and create images in a range of different colors, reports Alexandra-Simon Lewis for Wired. In the future, the technique could be used to make “bacteria produce more complex molecules on-demand by using light to stop and start chemical reactions.”
Washington Post reporter Travis Andrews writes that MIT researchers have created a workout suit with ventilating flaps embedded with bacteria that automatically open and close in response to sweat. Andrews explains that “as the bacteria relaxes and shrinks into itself, the cells pull away from the wearer, opening the flaps and letting fresh air flood in.”
New Scientist reporter Andy Coghlan writes that MIT researchers have engineered bacteria to produce full-color, living photocopies. Coghlan explains that the technique could “enable finer control of the bacteria grown in fermenters to churn out vital drugs, antibodies and materials. Another application could be using light to sculpt living biomaterials, such as tissues and organs for transplant.”
MIT researchers have developed a workout suit with vents that are triggered by bacteria to automatically open in response to sweat, reports Rob Verger for Popular Science. Verger explains that the researchers hope to apply the technology to create clothing that can, “produce a pleasant smell when you sweat.”
Daily Mail reporter Colin Fernandez writes that MIT researchers have developed a self-ventilating workout suit that can help keep athletes cool and dry while they exercise. Fernandez explains that the suit is embedded with harmless microbes that contract when they sense heat or cold, triggering flaps in the suit to open and close.
Wall Street Journal reporter James Hagerty writes about the life and legacy of Henri Termeer, a life member of the MIT Corporation known for his work as a pioneering leader in the field of biotechnology.
Xconomy reporter Ben Fidler writes about the life and legacy of Henri Termeer, a life member of the MIT Corporation who died at age 71. Institute Prof. Phillip Sharp explains that Termeer was, “a transformational leader in biotechnology of orphan diseases. Many children now have hope of a healthy life because of his vision and 40 years of creative business leadership.”
Henri Termeer, a life member of the MIT Corporation who was known as one of the founding fathers of the biotech industry, died at age 71, write Robert Weisman and Bryan Marquard for The Boston Globe. Termeer was, “a key leader in the biotech revolution that placed Massachusetts at the nexus of cutting-edge research and development.”
Appearing on WCVB-TV’s Chronicle, Provost Marty Schmidt explains why Kendall Square is a hub for innovation, highlighting how the region brings together organizations working on everything from computer science and biotech to brain and cognitive sciences. Schmidt explains that Kendall Square’s innovation ecosystem means research “coming out of MIT (can) be immediately translated to impact.”
MIT spinoff Sample6 has raised $12.7 million to create a better system for detecting bacteria in food, writes Luke Timmerman for Forbes. “The company has developed a technology that can target specific bioparticles, light them up and do it without enriching the sample,” explains Timmerman.
MIT researchers have developed a portable system that could produce biotech drugs on demand, reports Lisa Rapaport for Reuters. “The table-top machine has the potential to one day produce proteins to treat any number of a wide range of conditions like cancer, diabetes, heart attacks, and hemophilia,” writes Rapaport.
A portable device developed by MIT researchers uses programmable yeast to create drugs on demand, reports Jamie Ducharme for Boston Magazine. The device “could be a lifesaver for doctors working in vulnerable conditions, such as the battlefield, a remote village, or even an ambulance,” writes Ducharme.
Popular Science reporter Samantha Cole writes that MIT researchers have developed a laptop-sized, portable device that can produce biopharmaceuticals for doctors in remote locations. Cole explains that the device can “produce a single dose of treatment with a series of steps, using genetically engineered yeast cells as a mini 'factory' for a variety of customizable drugs.”
Boston Herald reporter Lindsay Kalter writes that MIT researchers have developed a portable pharmacy that can manufacture biopharmaceuticals and modify treatments. “Instead of relying on a cocktail that already exists, you can reprogram the reactor on demand to customize the treatment,” says Prof. Timothy Lu.
In a Boston Globe article about increasing interest in bio-agriculture, Robert Weisman highlights a number of MIT spinoffs, including Grove Labs and Ginkgo Bioworks. Weisman highlights the aquaponics systems Grove Labs is developing “complete with LED lighting, for growing fruit, vegetables, and herbs at home,” and how Ginkgo Bioworks is producing a “roster of ‘bio-products’ that include organic pesticides.”